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ARTI

:   Acute respiratory tract infections

IAV

:   Influenza A virus

IBV

:   influenza B virus

RSV

:   respiratory syncytial virus

PIVs

:   parainfluenza viruses

AdV

:   adenovirus

HMPV

:   human metapneumovirus

RV

:   rhinovirus

mPCRs

:   Multiplex PCR tests

DEUH

:   Dokuz Eylul University Hospital

RV/EV

:   rhinovirus/enterovirus

HCoV‐NL63

:   human coronaviruses NL63

HCoV 229E

:   human coronaviruses 229E

HCoV OC43

:   human coronaviruses OC43

HCoV HKU1

:   human coronaviruses HKU1

M. pneu

:   Mycoplasma pneumoniae

HboV

:   human bocavirus

HpeV

:   human parechovirus

ILI

:   influenza‐like illness

1. INTRODUCTION {#jmv25379-sec-0010}
===============

Acute respiratory tract infections (ARTIs) are the leading cause of global mortality and morbidity.[1](#jmv25379-bib-0001){ref-type="ref"} Incidence in children is similar in developed and developing countries, but mortality rates are higher in developing countries.[2](#jmv25379-bib-0002){ref-type="ref"} Nearly 70% of children between the ages of one and four with respiratory disease and 90% of infants under the age of one require hospitalization.[3](#jmv25379-bib-0003){ref-type="ref"}

Viruses are the etiologic agent pathogen in approximately 80% of ARTIs.[4](#jmv25379-bib-0004){ref-type="ref"} Influenza A virus (IAV), influenza B virus (IBV), respiratory syncytial virus (RSV), parainfluenza viruses (PIVs), adenovirus (AdV), human metapneumovirus (HMPV), and rhinovirus (RV) are frequently reported agents.[5](#jmv25379-bib-0005){ref-type="ref"}, [6](#jmv25379-bib-0006){ref-type="ref"}, [7](#jmv25379-bib-0007){ref-type="ref"} Clinical differentiation is not possible since there are no pathogen‐specific symptoms. Therefore, a specific diagnosis can only be made by microbiological tests.[8](#jmv25379-bib-0008){ref-type="ref"}

Viral pathogens can be detected by viral culture, direct immunofluorescence tests, rapid antigen tests, and/or nucleic acid tests. Although viral culture is traditionally the gold standard method, it is often slow and technically demanding, which causes problems in patient management. Direct immunofluorescence tests and rapid antigen assays can produce results in a relatively short‐time frame compared with viral cultures; however, their sensitivity and specificity are lower and can only be used for specific viruses.[9](#jmv25379-bib-0009){ref-type="ref"} Nucleic acid---based methods are often preferred for the diagnosis of viral respiratory infections, especially for hospitalized patients. These tests quickly identify the agent with high sensitivity and help to facilitate the appropriate management for both the patient and the infection control measures.[10](#jmv25379-bib-0010){ref-type="ref"} Specific polymerase chain reactions (PCRs; monoplex) can be used to identify single viral agents such as influenza A/B and RSV, however, their role is limited. Multiplex PCR tests (mPCRs) allow a fast detection of a wide range of respiratory viruses, therefore their importance and use are increasing with several commercial options.[11](#jmv25379-bib-0011){ref-type="ref"}

This study aimed to assess the role, distribution, and characteristics of viral respiratory agents in children, who were evaluated by mPCR in a single university hospital for the last 8 years.

2. MATERIALS AND METHODS {#jmv25379-sec-0020}
========================

Respiratory tract samples were collected from pediatric patients with ARTI symptoms and tested for viral pathogens at the Core Laboratory of Dokuz Eylul University Hospital (DEUH) between April 2011 and April 2018. The children were either seen at the outpatient departments or admitted to the pediatric wards of the same hospital. Results of 3162 patients between 0 and 18 years of age were evaluated retrospectively. Two different commercial kits based on multiplex real‐time PCR were used during the study period. An AusDiagnostics/Respiratory Pathogens 12 kit (AusDiagnostics, Beaconsfield, Australia) was used between April 2011 and December 2015, while a Fast Track Diagnostics/Respiratory Pathogens 21 kit (FTD 21; Fast Track Diagnostics, Junglinster, Luxemburg) was used between January 2016 and April 2018.

The AusDiagnostics test is based on multiplex tandem PCR method and identifies IAV, IBV, HMPV, PIV‐1, ‐2, ‐3, RSV, AdV, rhinovirus/enterovirus (RV/EV), and *Bordetella* spp. The FTD 21 test, using different primers and probes, detects 20 agents in five reaction tubes by mPCR. These agents are IAV, IAV subtype H1N1 (pandemic H1N1), IBV, human RV, human coronaviruses NL63 (HCoV‐NL63), 229E (HCoV 229E), OC43 (HCoV OC43) and HKU1 (HCoV HKU1), PIV‐1, ‐2, ‐3 and ‐4, *Mycoplasma pneumoniae*, human bocavirus (HBoV), HMPVA/B, RSVA/B, AdV, EV, and human parechovirus (HpeV). Both assays include internal control as well as negative and positive run controls. EZ1 Virus Mini Kit V 2.0 (QIAGEN, Hamburg, Germany) was used for nucleic acid extraction which was performed on the EZ1 Advanced XL (QIAGEN) device according to the manufacturer\'s instructions.

This study was approved by the Ethical Committee for Research of the Dokuz Eylul University (ref: 2018/20‐33).

3. RESULTS {#jmv25379-sec-0030}
==========

Among the 3162 tested samples of patients with ARTI symptoms, 85.4% (n = 2699) were from the patients admitted to the wards or intensive care units, while 14.6% (n = 463) were from outpatients. Study samples consisted of nasopharyngeal swabs (90.6%, 2865 of 3162), nasopharyngeal aspirates (8.6%, 272 of 3162), and bronchoalveolar lavage samples (0.8%, 25 of 3162). Among 3162 patients, 44.9% (1421 of 3162) were female and 55% (1741 of 3162) were male. The median age was 12 months (0‐211 months). Samples were grouped according to the age of the patients, Patients under the 2 years of age group accounted for 50% (1584 of 3162) of the study group while 24% (759 of 3162) were from 2 to 4 years, 15.1% (479 of 3162) were from 5 to 9 years and 10.7% (340 of 3162) were of 10 to 17 years age group.

A pathogen was detected in 1857 (58.7%) of the study samples. Distribution of PCR positive samples according to age groups was found as follows; 53% (978 of 1857) in less than 2 years age group, 24% (454 of 1857) in 2 to 4 years group, 15% (270 of 1857) in the 5 to 9 years group, and 8% (155 of 1857) in 10 to 17 years group. The positivity rate decreased significantly above 5 years of age (*P* \< 0.05).

The mean positivity rate was 44.4% during study period when the AusDignostics assay was used compared with 69.8% of the second part of the study using the Fast Track Diagnostics assay. The difference is statistically significant (*P* \< 0.001; Figure [1](#jmv25379-fig-0001){ref-type="fig"}A). RV/EV (17.6%) and RSV (9.2%) were the most commonly detected agents followed by IAV (4.8%; Table [1](#jmv25379-tbl-0001){ref-type="table"}). When the distribution of the agents according to years were examined, RV/EV was the most common agent for each year. RSV and coinfections took the second and third place in the frequency order except 2011 in which they are replaced by PIV‐3 and AdV. The study covered only the first 4 months of 2018 where coinfections were the most frequent cause of the respiratory infections in the studied group and followed by RV/EV and influenza A/B, respectively (Figure [1](#jmv25379-fig-0001){ref-type="fig"}B). When the distribution according to age groups was determined, The first three pathogens were RV/EV, RSV, and coinfections for less than 2 years; RV/EV, coinfections, and influenza A/B for 2 to 4 years; RV/EV, influenza A/B, and coinfections for 5 to 9 and 10 to 17 years (Table [2](#jmv25379-tbl-0002){ref-type="table"}).

![A, Positive and negative results according to the years. B, Distributions of the respiratory agents according to the years. EV, enterovirus; hMPV, human metapneumovirus; PIV, parainfluenza virus; RSV, respiratory syncytial virus; RV, rhinovirus](JMV-91-731-g001){#jmv25379-fig-0001}

###### 

Results (n) of 3162 respiratory samples analyzed by multiplex real‐time polymerase chain reaction in relation to month of the year during the study period (April 2011‐April 2018)

                                                                   Month                                                                                                                                     
  ---------------------------------------------------------------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- ----------------- ---------
  Rhinovirus/enterovirus                                           43        41        53        75        45        27        27        18        34        76        70        47        556 (17.6)        36.2
  Respiratory syncytial virus                                      65        90        68        31        10        2         1         0         0         1         3         21        292 (9.2)         19
  Influenza A virus                                                85        43        16        2         0         0         0         1         0         0         1         3         151 (4.8)         9.8
  Metapneumovirus                                                  25        32        18        19        4         2         2         0         0         0         1         1         104 (3.3)         6.8
  Adenovirus                                                       7         6         9         19        17        13        4         1         1         6         3         4         90 (2.8)          5.8
  Parainfluenza virus type 3                                       2         0         2         12        11        6         7         8         9         12        6         7         82 (2.6)          5.3
  Influenza B virus                                                22        26        18        5         1         0         0         0         0         0         0         3         75 (2.4)          4.9
  Coronavirus[^b^](#jmv25379-tbl1-note-0002){ref-type="fn"}        5         5         7         8         11        0         2         0         3         2         9         2         54 (1.7)          3.5
  Coronavirus (Cor‐43)                                             5         0         1         1         8         0         1         0         2         1         4         0         23                ...
  Coronavirus (Cor‐229E)                                           0         2         3         2         1         0         0         0         0         0         0         0         8                 ...
  Coronavirus (HKU1)                                               0         0         2         2         0         0         0         0         0         0         4         1         9                 ...
  Coronavirus (NL63)                                               0         3         1         3         2         0         1         0         1         1         1         1         14                ...
  Bocavirus[^b^](#jmv25379-tbl1-note-0002){ref-type="fn"}          11        11        7         3         4         2         2         1         0         3         3         3         50 (1.6)          3.3
  Parainfluenza virus type 1                                       5         0         0         1         0         1         1         0         5         16        7         1         37 (1.2)          2.4
  *Bordotella* spp[^a^](#jmv25379-tbl1-note-0001){ref-type="fn"}   0         0         0         1         2         5         4         4         1         0         0         1         18 (0.6)          1.2
  Parainfluenza virus type 2                                       1         1         0         0         1         1         2         1         0         2         4         2         15 (0.5)          1.0
  Parainfluenza virus type 4                                       3         0         0         0         0         1         2         0         1         0         2         2         11 (0.3)          0.7
  **Total positive with one agent**                                **274**   **255**   **198**   **176**   **106**   **60**    **54**    **34**    **54**    **118**   **109**   **97**    **1535 (48.5)**   **100**
  Samples with two agents positive                                 50        63        48        40        19        12        5         2         4         13        12        25        293 (9.3)         
  Samples with three agents positive                               10        2         8         1         3         0         0         0         0         3         1         1         29 (0.9)          
  **Total positive with two and three agents**                     **60**    **65**    **56**    **41**    **22**    **12**    **5**     **2**     **4**     **16**    **13**    **26**    **322 (10.2)**    
  **Total positive samples**                                       **334**   **320**   **254**   **217**   **128**   **72**    **59**    **36**    **58**    **134**   **122**   **123**   **1857 (58.7)**   
  **Total negative samples**                                       147       113       138       171       121       89        59        82        75        78        113       119       **1305 (41.3)**   
  \% of total positive                                             69.5      73.9      64.8      55.9      51.4      44.7      50        30.5      43.6      63.2      51.9      50.8                        
  **Total samples**                                                **481**   **433**   **392**   **388**   **249**   **161**   **118**   **118**   **133**   **212**   **235**   **242**   **3162 (100)**    

Data between April 2011‐ December 2015.

Data between January 2016 -- April 2018.

Bold entries are showing the total (cumulative) number of the specified group of subjects shown in above lines.

John Wiley & Sons, Ltd.
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###### 

All of the agents according to the age groups

                                  Age group                                 
  ------------------------------- ----------- --------- --------- --------- ----------
  Rhinovirus/enterovirus          268         155       77        56        556
  Respiratory syncytial virus     215         45        20        12        292
  Influenza A/B virus             79          58        56        33        226
  Metapneumovirus                 49          35        14        6         104
  Adenovirus                      35          21        24        10        90
  Parainfluenza virus 3           59          12        7         4         82
  Coronavirus                     25          10        11        8         54
  Coronavirus (Cor‐43)            12          3         5         3         23
  Coronavirus (Cor‐229E)          4           2         0         2         8
  Coronavirus (HKU1)              1           4         4         0         9
  Coronavirus (NL63)              8           1         2         3         14
  Parainfluenza virus 1           21          11        3         2         37
  Bocavirus                       23          11        13        3         50
  *Bordotella* spp                17          1         0         0         18
  Parainfluenza virus 2           10          3         1         1         15
  Parainfluenza virus 4           7           2         2         0         11
  Coinfections                    182         84        40        16        322
  **Total positive samples, n**   **990**     **448**   **268**   **151**   **1857**
  **Positive samples, %**         62.9        57.2      58        43.6      58.7
  **Coinfections, %**             11.6        10.7      8.6       4.6       10.2
  **Total samples, n**            **1572**    **782**   **462**   **346**   **3162**

Bold entries are showing the total (cumulative) number of the specified group of subjects shown in above lines.

John Wiley & Sons, Ltd.
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Among the parainfluenza viruses, PIV‐3 was the most frequently detected subtype, followed by PIV‐1, ‐2, and ‐4, respectively (Table [1](#jmv25379-tbl-0001){ref-type="table"}).

Bocavirus was positive in 94 cases (monoinfection 50 cases and coinfection 44 cases). Coinfections of bocaviruses with rhinovirus (15 of 44), RSV (9 of 44), and influenza A/B (5 of 44) were found to be frequent. Coronaviruses were positive in 98 cases (monoinfection 54 cases and coinfection 44 cases). HCoV OC43 was seen in 43% (42 of 98), HCoV‐NL63 in 31% (30 of 98), HCoV HKU1 in 15% (15 of 98), and HCoV 229E in 11% (11 of 98) of the patients. Coinfections were often associated with rhinovirus (17 of 44) and RSV (14 of 44). There was no positive result for HpeV during the study period.

In this study, *Bordetella* spp, which was the only bacterial agent in the test panel used in 2011‐2015 period. It was detected in a total of 28 cases as 18 monoinfections and 10 coinfections. The majority (96.4%; 27 of 28) of them were children younger than 3 months.

The prevalence of coinfections, where two or more agents were associated, was 10.2% (322 of 3162) in this study, detected especially in children under the age of 5 years. Prevalence was 11.6% (182 of 1572), 10.7% (84 of 782), 8.6% (40 of 462), and 4.6% (16 of 346), respectively, according to the increasing age groups (Table [2](#jmv25379-tbl-0002){ref-type="table"}). RV/EV (32%, 103 of 322) and RSV (25.2%, 81 of 322) were responsible for the majority of the coinfections (Figure [2](#jmv25379-fig-0002){ref-type="fig"}). Frequent coinfections were RV/EV with RSV (12.4%, 40 of 322), RV/EV with AdV (6.8%, 22 of 322), RSV with AdV (5.6%, 18 of 322), rhinovirus with coronavirus (5.3%, 17 of 322), rhinovirus with bocavirus (4.7%, 15 of 322) and RSV with coronavirus (4.3%, 14 of 322).

![Evaluation of the monoinfection and coinfection distribution. AdV, adenovirus; EV, enterovirus; hMPV, human metapneumovirus; MPV, metapneumovirus; PIV, parainfluenza virus; RSV, respiratory syncytial virus; RV, rhinovirus](JMV-91-731-g002){#jmv25379-fig-0002}

When Table [1](#jmv25379-tbl-0001){ref-type="table"} carefully examined two different distributions of pathogens determined, the first one was between RV/EV and AdV showing detection throughout the year (Figure [3](#jmv25379-fig-0003){ref-type="fig"}A). The second one was among influenza A/B, RSV, and HMPV, showing a similar seasonal distribution although there were some shifts between months of different years (Figure [3](#jmv25379-fig-0003){ref-type="fig"}B). These similar distributions make it difficult to predict the virus by the season and point out the importance of microbiological evaluation for an accurate diagnosis. Although RV/EV was detected in all months during the study period, the frequency increased in October and November as seen in Table [3](#jmv25379-tbl-0003){ref-type="table"}.

![A, Distribution of rhinovirus/enterovirus and adenovirus according to the month. B, Distribution of RSV, metapneumovirus and influenza A/B according to the months. RSV, respiratory syncytial virus](JMV-91-731-g003){#jmv25379-fig-0003}

###### 

Distribution of the rhinovirus and enterovirus according to the months

                                                                         Month                                                          
  ---------------------------------------------------------------------- ------- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ------------
  Rhinovirus/enterovirus[^a^](#jmv25379-tbl3-note-0001){ref-type="fn"}   12      11   15   32   20   9    20   10   17   19   28   30   223 (40.1)
  Rhinovirus[^b^](#jmv25379-tbl3-note-0002){ref-type="fn"}               29      30   37   42   25   18   8    7    17   57   41   17   328 (58.9)
  Enterovirus[^b^](#jmv25379-tbl3-note-0002){ref-type="fn"}              2       0    1    1    0    0    0    0    0    0    1    0    5 (0.9)
  Total                                                                  43      41   53   75   45   27   28   17   34   76   70   47   556 (100)

AusDiagnostics assay results, RV and EV are grouped as one.

Fast Track Diagnostics assay results, RV and EV are separated.

John Wiley & Sons, Ltd.
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4. DISCUSSION {#jmv25379-sec-0040}
=============

The role and importance of respiratory viruses have become more easily detectable by the use of nucleic acid---based tests in clinical laboratories. Thus it became possible to obtain detailed epidemiological data and to manage the patients better.

Our study retrospectively assessed the respiratory tract viruses detected in children with ARTI symptoms of 0 to 18 years between 2011‐2018. Two different assays were used during the study period. Ausdiagnostics assay covered a panel of 12 pathogens, while the Fast Track Assay tested for 21 agents. The wider coverage of pathogens resulted in a significantly higher rate of positive test results. In the study, RV/EV (17.6%) was the most frequently identified pathogen for all age groups and for every year without any seasonal difference. Using an assay enabling to separate rhinovirus from enterovirus made it possible to detect the importance of rhinovirus as the dominant type. Rhinoviruses have been reported as the most frequently detected agents in different parts of the world. In a US study using a commercial multiplex test, 66% of samples taken from pediatric cases were positive and RV was the most frequent causative agent between January 2014 and 2015. They also observed that RV was detected throughout the year with a peak in spring and autumn. Another 8‐year study from Scotland reported RV as the most common etiologic agent detected in respiratory tract samples for a group of patients with a median age of 27. Similar to the previous study, RV detected throughout the year with a peak in September. A Korean study in which the majority of the patients were children also reported RV as the number one etiologic factor.[6](#jmv25379-bib-0006){ref-type="ref"}, [12](#jmv25379-bib-0012){ref-type="ref"}, [13](#jmv25379-bib-0013){ref-type="ref"}

RSV (9.2%) was the second most common viral agent after RV in this study. It was particularly detected during winter and spring months with a peak between January and March. Consistent with our study, RSV is observed more frequently in winter months in many studies from different regions.[14](#jmv25379-bib-0014){ref-type="ref"} RSV and HMPV were usually seen in children under five years of age as the cause of bronchiolitis and pneumonia. In our study, the age relation was significant for RSV and HMPV which were detected in 89% (260 of 292) and 81% (84 of 104) of children under 5 years, respectively. Similar to RSV, HMPV infections were frequently seen in winter and spring months as it was the case in our study while 90% of the HMPV cases were detected between January and April.[15](#jmv25379-bib-0015){ref-type="ref"}

IAV and IBV were detected with a frequency of 4.8% and 2.4%, respectively, and peaked between January and March. The presence of RSV and HMPV in circulation during the same period was notable, which necessitates the use of virological methods for the differential diagnosis of influenza‐like illness (ILI). Circulation of other respiratory viruses during the influenza season was also reported by the reference laboratory of the Turkish Public Health Institution with a warning of the high possibility of noninfluenza viruses causing ILI at the beginning and end of the season.[16](#jmv25379-bib-0016){ref-type="ref"}

ADVs detected in 90 cases which were mostly (64.4%) seen during spring and early summer months. Although seasonal characteristics of adenoviral infections affected by the geographical region and genotype of the virus, such infections are reported to be more common between September and February in the literature.[17](#jmv25379-bib-0017){ref-type="ref"}, [18](#jmv25379-bib-0018){ref-type="ref"}

There are four subtypes of PIVs (1‐4) which may cause croup, pharyngitis, laryngitis, tracheobronchitis, bronchiolitis, and/or pneumonia.[19](#jmv25379-bib-0019){ref-type="ref"} PIV‐3 was the most commonly detected subtype in our study, followed by PIV‐1, ‐2, and ‐4. PIV‐3 is detected more frequently in April, May, and October. It was not possible to detect the seasonal relation of other PIV subtypes due to a small number of cases. In other studies, PIV‐3 was also reported as the most common subtype followed other PIVs similar to our findings.[20](#jmv25379-bib-0020){ref-type="ref"}, [21](#jmv25379-bib-0021){ref-type="ref"} They were frequently detected during spring and early summer months.

Bocavirus, after being identified in 2005 has been isolated from 1.5% to 19% of the respiratory tract samples of children who were admitted to the hospital due to respiratory viral disease.[22](#jmv25379-bib-0022){ref-type="ref"} Bocavirus causes coinfections up to 90% of the cases with other viruses such as influenza, rhinovirus, parainfluenza, RSV, and metapneumovirus.[23](#jmv25379-bib-0023){ref-type="ref"}, [24](#jmv25379-bib-0024){ref-type="ref"} The prevalence of bocavirus was 2.8% in our study with a coinfection frequency of 48.8%, mainly associated with rhinovirus/enterovirus, RSV, and influenza A/B. Infections were seen throughout the year without a clear seasonal relation although 58% (29 of 50) of cases were between January and March which is parallel to the other reported studies.[25](#jmv25379-bib-0025){ref-type="ref"}, [26](#jmv25379-bib-0026){ref-type="ref"}, [27](#jmv25379-bib-0027){ref-type="ref"}

Coronaviruses were identified nearly 5% of the patients, with OC43 being the most frequent subtype followed by NL63, HKU1, and 229E. Coinfections with rhinovirus or RSV were seen in almost half of the samples. These infections were detected in almost all months except June and August. It was reported that coronavirus infections peaked mainly in winter without any significant difference between the four subtypes in terms of seasonality and origin (community or hospital‐acquired) of the infection.[28](#jmv25379-bib-0028){ref-type="ref"}, [29](#jmv25379-bib-0029){ref-type="ref"}

*Bordetella* spp is an agent that can be mistaken as viral infection since can lead to prolonged cough and severe infections in infants, and young children. There were only 28 patients with *Bordetella* infections in our study which were seen in patients less than 3‐months old, except for one. Although can be seen at any age, pertussis is more frequent and cause more severe disease in children younger than 3‐months--old because of lack of primary vaccination.[30](#jmv25379-bib-0030){ref-type="ref"} High vaccine coverage (at least 95%) is necessary to protect children against vaccine‐preventable diseases with the herd immunity. The importance of herd immunity is nicely described by an Italian study of three cases of *B. pertussis*, one 16‐month old and two less than a month old children showing that reduced immunity of the child\'s family over the years increases the risk of infection especially in infants lack maternal immunity with a more severe clinical presentation. In Italy, vaccination coverage dropped from 97% in 2000s to 92% in the areas where the cases were reported due to the parental opposition to vaccination.[31](#jmv25379-bib-0031){ref-type="ref"}

Nucleic acid---based multiplex tests detect viral coinfections more frequently, with a prevalence up to 40% depending on the method and the study. Coinfections were detected in 10.2% of the samples in this study group. The prevalence decreased significantly at the ≥ 5 years of age (*P* \< 0.05). The most common viruses detected in coinfections were RV/EV and RSV. Clinical importance of the viral coinfections is not clear as several studies detected no effect on the severity of the disease.[32](#jmv25379-bib-0032){ref-type="ref"}, [33](#jmv25379-bib-0033){ref-type="ref"}

The main limitation of this study is its retrospective design. It was not possible to evaluate the effect of multiplex PCR assay on patient management since the clinical data were limited. However, the increasing number of test orders over the years suggests that test results were supportive of the clinical decisions. Also, the 8‐year--long study period allowed a better assessment of the factors affecting respiratory virus prevalence such as age and season. Some of the agents such as bocavirus, HCoV, PIV‐4, and *Bordetella* spp. could only be detected by one of the two tests used during the study, therefore, evaluated only for the years related commercial kit was used.

In conclusion, the RV/EV group, namely rhinovirus, was the most common virus for all age groups during the study period. The second commonly detected virus was RSV for children younger than 2 years of age, influenza A/B for children older than 5 years of age. The seasonal cycle of influenza virus is well known. The same relation was also seen for RSV and metapneumovirus. Virological diagnosis of the pathogen was important since these three viruses caused infections in the same season. Surveillance and monitoring of the annual/seasonal characteristics of the respiratory viruses are critical in predicting and detecting epidemics and pandemics. In this way, it would be possible to diagnose the correct pathogen and prevent inappropriate antimicrobial treatment.
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